John H. Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and professor of psychiatry, of neuroscience, and of psychology, and chair of the Yale Department of Psychiatry, has been chosen to obtain the 2026 Connecticut Medal of Technology.
Krystal and representatives from the opposite honoree, the RTX Technology Research Center (RTRC), will settle for their medals at a ceremony to be organized. They shall be acknowledged on the Connecticut Academy of Science and Engineering’s Annual Dinner on May 19.
Krystal is being honored “for the discovery of the rapid antidepressant actions of ketamine, the most important clinical advance in psychiatry in the current era, leading to the development of esketamine, the first mechanistically novel FDA-approved antidepressant in over 50 years.”
RTRC is being honored “for developing era-defining breakthroughs in commercial aviation and defense for over 95 years, during which time its scientists and engineers have pushed the limits of technology and science by taking on its customers’ toughest challenges and redefining how we connect and protect our world.”
Krystal is a number one knowledgeable on the neurobiology and therapy of psychiatric issues. His work hyperlinks psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience to review the neurobiology and therapy of issues, together with alcohol use dysfunction, despair, PTSD, and schizophrenia.
He and his collaborators recognized mechanisms in sufferers underlying these antidepressant results: enhanced glutamate launch (13C-MRS), restoration of cortical practical connectivity deficits (fMRI), restoration of synaptic density (PET), and novel mechanisms for enhancing or sustaining these results through mTORC1 inhibition and glycine-site NMDA-R modulation.
He additionally studied the neurobiology and therapy of alcohol use dysfunction, PTSD, and schizophrenia. He recognized the primary organic mechanism in PTSD together with his colleagues within the early Nineties. Most not too long ago, he co-founded the National PTSD Brain Bank and co-led the primary well-powered transcriptomic examine of PTSD. His research of schizophrenia recognized cortical mechanisms underlying signs and predicted the emergence of medication that might deal with schizophrenia with out blocking dopamine D2 receptors. The first drug of this sort, Cobenfy, was accepted by the FDA in 2024.
Krystal earned his Bachelor of Arts in behavioral sciences from the University of Chicago in 1980, his MD from Yale School of Medicine in 1984, and accomplished psychiatry residency coaching at Yale University in 1988. He is a co-inventor with a number of patents which were licensed or are being licensed to pharmaceutical or digital healthcare firms. In addition, he has contributed to the founding of two pharmaceutical firms – Biohaven Pharmaceuticals and Freedom Biosciences.
Krystal is chief of psychiatry for the Yale New Haven Health System and co-leads the Yale Center for Clinical Investigation. He co-directs the NIAAA Center for the Translational Neuroscience of Alcohol and leads the Clinical Neuroscience Division of the National Center for PTSD (VA).
His main latest awards embrace the Sarnat Prize of the National Academy of Medicine (2023), the ACNP Barbara Fish Memorial Award (2023), the American Psychiatric Association Nasarallah Family Neuroscience Award (2023), the British Pharmacologic Society’s Sir John Gaddam Memorial Lecture and Medal (2022), and the Gold Medal Award of the Society of Biological Psychiatry (2018).
Krystal is a member of the U.S. National Academy of Medicine and the Connecticut Academy of Science and Engineering (CASE), a fellow of the American Association for the Advancement of Science, and previous co-chair of the Neuroscience Forum of the U.S. National Academies of Science, Engineering, and Medicine. He chaired the NIMH Board of Scientific Counselors and served on the National Advisory Councils for NIMH and NIAAA.
As editor of Biological Psychiatry since 2006, he oversaw the creation of a household of journals, together with BP: Cognitive Neuroscience and Neuroimaging (2015) and BP: Global Open Science (2020). He is a previous president of the American College of Neuropsychopharmacology (ACNP) and the International College of Neuropsychopharmacology (CINP).
RTRC is Connecticut’s premier analysis and improvement facility, and an innovation hub for RTX and its enterprise models, together with Connecticut-based Pratt & Whitney and Collins Aerospace. For greater than 95 years, the RTRC’s workers of engineers and scientists has tackled the hardest challenges in aviation and protection.
The Connecticut Medal of Technology is awarded to people, groups, and organizations for his or her excellent contributions to the financial, environmental, and social well-being of Connecticut and the nation by the promotion of know-how, technological innovation, or the event of the technological workforce. By highlighting the significance of technological innovation, the award additionally seeks to encourage future generations to arrange for and pursue technical careers to maintain Connecticut and the nation on the forefront of world know-how and financial management.
Modeled after the National Medal of Technology and Innovation, this award is bestowed by the State of Connecticut by route of the Office of the Governor, with the help of the Connecticut Academy of Science and Engineering, in alternate years with the Connecticut Medal of Science.
Click here to see a list of past awardees.
The Connecticut Academy of Science and Engineering was created by the General Assembly in 1976 to offer knowledgeable recommendation on science and know-how to the folks and the state of Connecticut, and to assist the use of science and know-how to enhance human welfare and the economic system.